Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca settles Ranbaxy lawsuit

AstraZeneca has settled a lawsuit out-of-court it filed against Ranbaxy Laboratories for patent infringement of one its proton-pump inhibitor Nexium
AstraZeneca (AZ) has settled a lawsuit out-of-court it filed against Ranbaxy Laboratories for patent infringement of one its proton-pump inhibitor (PPI) Nexium.

The two companies have notified the US District Court of New Jersey of the settlement agreement, which will see AZ licence Ranbaxy to commence sales of the generic version of Nexium. Under the terms of the agreement, Ranbaxy has conceded that all six of the AZ patents contested in the litigation are valid and enforceable. It also accepts sales of the generic product would have infringed four of AZ's patents.

Neil McCrae, spokesman for AZ, explained that the agreement does not involve a financial settlement of any kind

"We as a mater of course will defend our intellectual property against what we believe to be a generic challenge," he concluded.

David Brennan, chief executive officer of AZ, said: "I believe that this agreement is the right business decision and gives increased clarity and stability to allow us to continue investing substantially in our growing pipeline of new medicines."

Ranbaxy submitted an abbreviated new drug application (NDA) to the US Food and Drug Administration (FDA) for a generic drug originally patented by AZ.

Nexium patent litigations filed by AZ against Teva/Ivax and Dr Reddy's laboratories remain outstanding.

 

Related links:
AstraZeneca settles with Teva over Nexium

 

15th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics